Ad vectors have the ability to deliver transgenes to a variety of cell types, in vitro and in vivo, and unlike retrovirus based vectors, Ad vectors can also efficiently transduce mitotically quiescent cells. Therefore, the potential treatment of many different diseases, both genetic and non-genetic can be envisioned with the use of Ad vectors. For example, Ad vectors have been demonstrated to be capable of delivering genes to 1) liver cells for the potential treatment of many metabolic disorders, 2) muscle cells (skeletal and cardiac) for the potential treatment of myopathies and storage disorders, 3) brain and nervous system tissues for the potential treatment of neurologic diseases like Parkinson disease, and 4) respiratory epithelium for the treatment of pulmonary disorders like cystic fibrosis. In addition, many other common diseases like AIDS and various forms of cancer have all been demonstrated to be potentially treated by Ad mediated gene transfer strategies. While there is an enormous potential for the treatment of many human diseases, there are several problems with current Ad vectors that must be addressed before Ad mediated gene therapy becomes a clinical reality. The most serious problem with current Ad vectors is the transient duration of transgene expression after successful gene delivery into the tissues of immunocompetent animals. Other problems include the generation of replication competent Ad (RCA), and the inability of Ad vectors to carry larger genes or tissue-specific promoter/enhancer elements. This grant proposal outlines a series of experiments that will address each of the limitations of current Ad vectors. In so doing, we will isolate modified Ad vectors that are predicted to allow for longer durations of transgene expression in vivo, decrease the incidence of RCA generation, and significantly increase Ad vector carrying capacity. Initially, the modified Ad vectors will be analyzed in mouse models of liver and muscle cell gene therapy. The result will be the isolation of new Ad vectors capable of efficacious use in animal models of human disease, as well as for eventual use in the therapy of a great number of human conditions.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Research Project (R01)
Project #
5R01DK052925-03
Application #
6177742
Study Section
Medical Biochemistry Study Section (MEDB)
Program Officer
Mckeon, Catherine T
Project Start
1998-07-10
Project End
2002-05-31
Budget Start
2000-06-01
Budget End
2001-05-31
Support Year
3
Fiscal Year
2000
Total Cost
$216,655
Indirect Cost
Name
Duke University
Department
Pediatrics
Type
Schools of Medicine
DUNS #
044387793
City
Durham
State
NC
Country
United States
Zip Code
27705
Franco, Luis M; Sun, Baodong; Yang, Xiaoyi et al. (2005) Evasion of immune responses to introduced human acid alpha-glucosidase by liver-restricted expression in glycogen storage disease type II. Mol Ther 12:876-84
Everett, R S; Evans, H K; Hodges, B L et al. (2004) Strain-specific rate of shutdown of CMV enhancer activity in murine liver confirmed by use of persistent [E1(-), E2b(-)] adenoviral vectors. Virology 325:96-105
McVie-Wylie, A J; Ding, E Y; Lawson, T et al. (2003) Multiple muscles in the AMD quail can be ""cross-corrected"" of pathologic glycogen accumulation after intravenous injection of an [E1-, polymerase-] adenovirus vector encoding human acid-alpha-glucosidase. J Gene Med 5:399-406
Sun, Baodong; Chen, Y-T; Bird, Andrew et al. (2003) Packaging of an AAV vector encoding human acid alpha-glucosidase for gene therapy in glycogen storage disease type II with a modified hybrid adenovirus-AAV vector. Mol Ther 7:467-77
Amalfitano, Andrea (2003) Use of multiply deleted adenovirus vectors to probe adenovirus vector performance and toxicities. Curr Opin Mol Ther 5:362-6
Everett, R S; Hodges, B L; Ding, E Y et al. (2003) Liver toxicities typically induced by first-generation adenoviral vectors can be reduced by use of E1, E2b-deleted adenoviral vectors. Hum Gene Ther 14:1715-26
Sun, Bao-dong; Chen, Y-T; Bird, Andrew et al. (2003) Long-term correction of glycogen storage disease type II with a hybrid Ad-AAV vector. Mol Ther 7:193-201
Dhar, Sumeer; Bitting, Rhonda L; Rylova, Svetlana N et al. (2002) Flupirtine blocks apoptosis in batten patient lymphoblasts and in human postmitotic CLN3- and CLN2-deficient neurons. Ann Neurol 51:448-66
Rylova, Svetlana N; Amalfitano, Andrea; Persaud-Sawin, Dixie-Ann et al. (2002) The CLN3 gene is a novel molecular target for cancer drug discovery. Cancer Res 62:801-8
Ding, Enyu; Hu, Huimin; Hodges, Bradley L et al. (2002) Efficacy of gene therapy for a prototypical lysosomal storage disease (GSD-II) is critically dependent on vector dose, transgene promoter, and the tissues targeted for vector transduction. Mol Ther 5:436-46

Showing the most recent 10 out of 12 publications